Ivonescimab HARMONi-6 Lung Cancer Survival
Decision brief
Answer first · skim in under a minute
Akeso and Summit's recent lung cancer trial results indicate significant survival benefits. This article explores the implications for the pharmaceutical industry.
Akeso and Summit’s PD-1/VEGF bispecific ivonescimab extended survival in a closely watched lung cancer trial: HARMONi-6 showed a 34% reduction in death risk versus a PD-1 plus chemotherapy control in first-line squamous NSCLC, sharpening the debate over whether China Phase 3 wins will translate globally.
Contents10 sections
Key Takeaways
- HARMONi-6 (NCT05840016) reported OS HR 0.66 for ivonescimab plus chemo versus tislelizumab plus chemo in first-line advanced squamous NSCLC.
- Median OS was 27.9 months versus 23.7 months in the disclosed ITT analysis presented around ASCO 2026.
- The study was China-based and Akeso-sponsored; Summit holds broad ex-China rights and separate global trials.
- Summit’s U.S. BLA timeline (PDUFA November 14, 2026 for a different EGFR-mutant setting) should not be conflated with HARMONi-6 squamous OS.
What survival benefit did HARMONi-6 report?
In a May 31, 2026 PR Newswire release, Akeso said ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit versus tislelizumab plus chemotherapy in first-line advanced squamous NSCLC.
The company reported HR 0.66 (95% CI 0.50–0.87; P=0.0017) and median OS of 27.9 versus 23.7 months. That head-to-head OS win against an active PD-1 control is why the ASCO plenary drew competitive attention across the PD-1/VEGF class.
How is the trial designed and registered?
HARMONi-6 is listed as NCT05840016 on ClinicalTrials.gov. Public trial descriptions characterize a randomized, double-blind Phase 3 study in China comparing ivonescimab or tislelizumab with paclitaxel/carboplatin induction then maintenance monotherapy.
Primary endpoint framing centered on progression-free survival by independent review, with overall survival as a key secondary endpoint and an interim OS analysis timed for regulatory needs. Safety reviews must track VEGF-pathway risks such as hemorrhage alongside immune-related events.
How should Summit partnership economics be read?
Summit in-licensed ivonescimab from Akeso for large ex-China territories. Company updates have emphasized global development scale and a U.S. BLA accepted for filing in an EGFR-mutated non-squamous NSCLC post-EGFR TKI setting, with a PDUFA goal date of November 14, 2026.
Investors sometimes blur HARMONi-6 squamous first-line China OS with that U.S. filing. They are different populations, controls, and geographies. Competitive intelligence should keep three lanes: China squamous OS, global squamous/non-squamous Phase 3s, and the EGFR-mutant U.S. BLA clock.
What does this mean versus other PD-1/VEGF bispecifics?
HARMONi-6 raises the clinical bar that BioNTech/BMS pumitamig and Pfizer PF-08634404 programs will be measured against in first-line lung cancer. A China OS win does not end the debate about Western control arms, smoking epidemiology, or PD-L1 distribution differences.
For Merck, Roche, and other PD-1 franchise holders, the immediate task is stress-testing combo strategies and next-wave bispecific partnerships if global ivonescimab data later confirm OS superiority outside China.
What safety caveats belong in every briefing?
- Grade ≥3 treatment-related adverse events were higher with ivonescimab than tislelizumab in disclosed Lancet/ASCO materials.
- Grade ≥3 haemorrhage rates require explicit monitoring in VEGF-pathway bispecifics.
- China-only enrollment limits external validity until multi-region Phase 3 OS matures.
- Do not market HARMONi-6 as a U.S. label claim.
What remains unproven?
HARMONi-6 does not prove global first-line superiority over pembrolizumab-based standards, nor does it establish U.S. approvability for squamous NSCLC. Long-term OS curve shape, CNS outcomes, and quality-of-life differentials need full publications and global datasets. Unsourced “extends survival” claims without HR, medians, and NCT IDs are omitted here.
Investors should also avoid treating a single China OS hazard ratio as a global peak sales forecast. Multi-region Phase 3 controls, PD-L1 distribution, and smoking epidemiology can move both efficacy and safety. Until those readouts mature, HARMONi-6 is a landmark regional signal—not a finished worldwide label story.
Related NovaPharma coverage
- BioNTech, Pfizer Bispecific Data at ASCO
- Lung cancer disease hub
- FDA approves Keytruda for adjuvant NSCLC treatment
Frequently Asked Questions
What did the Akeso and Summit lung cancer trial show?
In Phase 3 HARMONi-6 (NCT05840016), ivonescimab plus chemotherapy improved overall survival versus tislelizumab plus chemotherapy in first-line advanced squamous NSCLC, with HR 0.66 and median OS 27.9 versus 23.7 months in the disclosed ITT analysis.
Was HARMONi-6 a global trial?
No. HARMONi-6 was a China-conducted Phase 3 study sponsored by Akeso. Summit holds ex-China rights to ivonescimab and is running separate global registrational programs; China OS results do not automatically equal global outcomes.
What is ivonescimab’s U.S. regulatory status?
Summit disclosed FDA acceptance of a BLA for an EGFR-mutant non-squamous NSCLC chemotherapy combination setting with a PDUFA goal date of November 14, 2026. That filing is distinct from the HARMONi-6 squamous first-line China OS dataset.
Primary Sources
Akeso pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…